Literature DB >> 10540649

Abdominal US for diagnosis of pancreatic tumor: prospective cohort analysis.

B M Karlson1, A Ekbom, P G Lindgren, V Källskog, J Rastad.   

Abstract

PURPOSE: To elucidate the accuracy of abdominal ultrasonography (US) in the diagnosis of pancreatic tumors.
MATERIALS AND METHODS: In all patients referred for pancreatic US during 1988-1990, data on malignant disease and survival were analyzed by using the Swedish Death and Cancer Registries. Nine hundred nineteen patients were entered into the analysis. In 140 of them, a clinical diagnosis of tumor in the pancreatic area was confirmed within 1 year after US. These tumors were primary pancreatic tumors (n = 102), common bile duct and duodenal cancers (n = 17), and metastases in the pancreatic area (n = 21).
RESULTS: The sensitivity of US in the detection of all tumors in the pancreatic area was 88.6% (124 of 140 patients), which was similar to that for the detection of exocrine pancreatic cancer, 90% (79 of 88 patients). There were nine false-positive US examinations, for a specificity of 98.8% (770 of 779 patients). Systematic sampling of 94 investigations confirmed an association between US accuracy and presence of clinical symptoms of pancreatic cancer. Significant differences in the sensitivity (P < .05) and accuracy (P < .01) of diagnosis were observed between three experienced investigators.
CONCLUSION: Study results support the use of US as a first-line diagnostic examination in patients suspected of having pancreatic tumor. Dependency on the investigator's experience with US mandates continuous evaluation of its performance.

Entities:  

Mesh:

Year:  1999        PMID: 10540649     DOI: 10.1148/radiology.213.1.r99oc25107

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  19 in total

Review 1.  The role of transabdominal ultrasonography, helical computed tomography, and magnetic resonance cholangiopancreatography in diagnosis and management of pancreatic disease.

Authors:  I D Norton; J E Clain
Journal:  Curr Gastroenterol Rep       Date:  2000-04

2.  Guidelines for the management of patients with pancreatic cancer periampullary and ampullary carcinomas.

Authors: 
Journal:  Gut       Date:  2005-06       Impact factor: 23.059

3.  Primary sarcoma of the pancreas, a rare histopathological entity. A case report with review of literature.

Authors:  Peter Ambe; Christian Kautz; Shawqi Shadouh; Silvia Heggemann; Lothar Köhler
Journal:  World J Surg Oncol       Date:  2011-08-03       Impact factor: 2.754

Review 4.  Investigation of abdominal pain to detect pancreatic cancer.

Authors:  J Ashley Guthrie; Maria B Sheridan
Journal:  BMJ       Date:  2008-05-10

Review 5.  Advances in diagnosis, treatment and palliation of pancreatic carcinoma: 1990-2010.

Authors:  Chakshu Sharma; Karim M Eltawil; Paul D Renfrew; Mark J Walsh; Michele Molinari
Journal:  World J Gastroenterol       Date:  2011-02-21       Impact factor: 5.742

6.  Echo-enhanced ultrasound--a new imaging modality for the differentiation of pancreatic lesions.

Authors:  Steffen Rickes; Peter Malfertheiner
Journal:  Int J Colorectal Dis       Date:  2005-06-07       Impact factor: 2.571

7.  Diagnosis of pancreatic cancer.

Authors:  Fumihiko Miura; Tadahiro Takada; Hodaka Amano; Masahiro Yoshida; Shigeru Furui; Koji Takeshita
Journal:  HPB (Oxford)       Date:  2006       Impact factor: 3.647

Review 8.  Imaging diagnosis of pancreatic cancer: a state-of-the-art review.

Authors:  Eun Sun Lee; Jeong Min Lee
Journal:  World J Gastroenterol       Date:  2014-06-28       Impact factor: 5.742

Review 9.  Multimodality imaging of pancreatic ductal adenocarcinoma: a review of the literature.

Authors:  Shailesh V Shrikhande; Savio George Barreto; Mahesh Goel; Supreeta Arya
Journal:  HPB (Oxford)       Date:  2012-06-14       Impact factor: 3.647

Review 10.  Pancreatic involvement in small cell lung cancer.

Authors:  Ugur Gonlugur; Arzu Mirici; Muammer Karaayvaz
Journal:  Radiol Oncol       Date:  2014-01-22       Impact factor: 2.991

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.